Benefit from massive undervaluation of our new cannabis pearl! This comany is one of the big beneficiaries of the global cannabis mega trend! You can read and download the complete company introduction in our next newsletter issue. Subscribe to our free newsletter now!
Our buying arguments for our new model portfolio candidate:
- Top management with pharmaceutical background. Team members held before senior positions at pharmaceutical companies e.g. at Boehringer Ingelheim.
- The Company is well positioned to benefit from the global cannabis boom
- Strong business plan with unique growth strategy
- First manufacturing order placed on 100,000 CBD oil bottles –this first product is already on the market – Strong sales growth expected!
- Using the patented micelle technology, the resulting 1% solution is very effective as it significantly improves bioavailability (up to 15 times higher than competing products) and gives consumers greater consistency and effectiveness.
- Various other consumer-friendly products in preparation
- Completed a successful C$ 15 million capital increase in April 2019 – enough to reach the first targeted milestones of the business plan
- XXX has a strong patent portfolio (15 patents that allow targeted processing of cannabinoids and inclusion in countless products)
- Pharmaceutical products require high product quality, consistent dosage and consistency> all the points that XXX’s unique cannabis formulation can offer!
- Cannabis 2.0 profiteer: A total of 10 pharmacological product candidates covering a variety of therapeutic conditions.
- Cannabis 3.0 Profiteer: The unique patent portfolio makes our new top pick a prime takeover target or JV partner for companies in the consumer goods industry.
- (Still) low market capitalization of only C$ 65 million
Source: Stockcharts.com, prices as of June 18, 2019
Your Cannabisradar.info editorial team monitors and analyzes the cannabis sector for you. Benefit from our unique network built up over decades to brokers, analysts and industry experts!